PMA device
SURGIFOAM® Absorbable Gelatin Sponge
Ferrosan Meidcal Devices A/S · Agent, Absorbable Hemostatic, Collagen Based (LMF, Class III) · First FDA decision Jul 29, 2004, newest Sep 18, 2026Surgical bleeding and hemostasis
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
9
PMA pathway
Device trials
1
Naming "SURGIFOAM"
MAUDE reports
66
Brand "SURGIFOAM", since 2015
PubMed studies
20
Mentioning "SURGIFOAM"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing SURGIFOAM® Absorbable Gelatin Sponge
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 6 of 9 decisions filed under this name.
- SURGIFOAM® Absorbable Gelatin SpongePMA supplement
P990004-S080 · Decided Sep 18, 2026 · 177 days after receipt · Normal 180 Day Track
Device type: Agent, absorbable hemostatic, collagen based (LMF) · General & Plastic Surgery
- SURGIFOAM Absorbable Gelatin Sponge, U.S.P.PMA supplement
P990004-S039 · Decided Oct 19, 2021 · 515 days after receipt · Normal 180 Day Track No User Fee
Device type: Agent, absorbable hemostatic, collagen based (LMF) · General & Plastic Surgery
- SURGIFOAM ABSORBABLE GELATIN SPONGE, USPPMA supplement
P990004-S028 · Decided Feb 5, 2016 · 336 days after receipt · Normal 180 Day Track No User Fee
Device type: Agent, absorbable hemostatic, collagen based (LMF) · General & Plastic Surgery
3 more FDA decisions with a free account
Older decisions: P990004-S012, P990004-S007, P990004-S005
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "SURGIFOAM", any status and sponsor, newest update first.
- ACCEL Absorbable HemostatPivotal-lookingStatus unknown
Hemostasis, LLCNot on our public-company list
NCT04728087 · 216 participants (planned) · Start Oct 26, 2021 · Primary completion Nov 30, 2024
Device: ACCEL® Absorbable Hemostat Powder; Gelfoam® (Absorbable Gelatin Sponge, Pfizer Manufacturer Part Number 0342-01) · For: Hemostasis
Sites: Los Angeles, California; Kansas City, Missouri; St Louis, Missouri · 7 sites in all
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "SURGIFOAM", and for the whole product code for context.
This brand
66 reports: 2 malfunction, 58 injury, 5 death
Whole product code LMF
1,445 reports: 207 malfunction, 1,171 injury, 61 death
Newest reports for this brand
3008478369-2026-00036 · Received Sep 24, 2026
Device type: Agent, Absorbable Hemostatic, Collagen Based (LMF)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Hypersensitivity/Allergic reaction
- SURGIFOAMMalfunction
2210968-2026-100014 · Received Jun 5, 2026 · Event dated May 8, 2026
Device type: Agent, Absorbable Hemostatic, Collagen Based (LMF)
Device problem as coded: Device Contaminated During Manufacture or Shipping
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
2210968-2026-100005 · Received May 5, 2026 · Event dated Nov 26, 2024
Device type: Agent, Absorbable Hemostatic, Collagen Based (LMF)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Fistula
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
- SURGIFOAM" Absorbable Gelatin Powder Kit, Product Code 1979.Open, Classified
Z-1881-2024 · Started Apr 23, 2024 · Posted by FDA May 22, 2024
Reason given: Some applicator tips from these lots had open seals.
Cause as FDA categorized it: Under Investigation by firm · Device type: Agent, Absorbable Hemostatic, Collagen Based (LMF)
Mckesson Medical-Surgical Inc. Corporate Office
Z-1584-2022 · Started May 25, 2022 · Posted by FDA Aug 26, 2022
Reason given: Facility Temperature excursions (from June 2021-August 2021) prior to delivery; exposure to higher temperatures may have impacted product effectiveness. All lots received between 06/01/21-9/30/21.
Cause as FDA categorized it: Environmental control · Device type: Agent, Absorbable Hemostatic, Collagen Based (LMF)
Z-0292-2013 · Started Aug 21, 2012 · Posted by FDA Nov 16, 2012
Reason given: SURGIFLO Hemostatic Matrix Kit & SURGIFLO Hemostatic Matrix Kit with Thrombin have an issue within the packing process where a cut could potentially breach the double Tyvek pouch of the packaging.
Cause as FDA categorized it: Packaging · Device type: Agent, Absorbable Hemostatic, Collagen Based (LMF)
2 more recall records with a free account
Published research
The most relevant PubMed records for "SURGIFOAM"[tiab]. The summary above synthesizes these.
- Comparative Efficacy of Two Hemostatic Agents in Post-Extraction Bleeding Control Following Mandibular Third Molar Surgery: A Randomized Clinical Trial.
Pesce G, Sartoretto SC, Resende RFB, et al. · J Funct Biomater · 2025
- Gelatin sponge to close a tract after large-bore transhepatic access: tips for success.
Mohammad Nijres B, Justino H, Law I, et al. · Cardiol Young · 2023
- Pre-clinical subdural tissue reaction and absorption study of absorbable hemostatic devices.
Barbolt TA, Odin M, Léger M, et al. · Neurol Res · 2001
- Topical platelet-rich plasma as a possible treatment for olfactory dysfunction-A randomized controlled trial.
Duffy A, Naimi B, Garvey E, et al. · Int Forum Allergy Rhinol · 2024Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Advances in the development and optimization strategies of the hemostatic biomaterials.
Guo Y, Cheng N, Sun H, et al. · Front Bioeng Biotechnol · 2022Review
- Perioperative Considerations in Alpha-Gal Syndrome: A Review.
Leder J, Diederich A, Patel B, et al. · Cureus · 2024Review
- Thromboemboli, acute right heart failure and disseminated intravascular coagulation after intraoperative application of a topical hemostatic matrix.
Ferschl MB, Rollins MD · Anesth Analg · 2009Case Reports
- Natural History of Intracranial Absorbable Gelatin Powder.
Zwagerman NT, Agarwal N, Jankowitz BT · World Neurosurg · 2017Case Reports
- Formulation of the bivalent prostate cancer vaccine with surgifoam elicits antigen-specific effector T cells in PSA-transgenic mice.
Karan D · Vaccine · 2017Research Support, N.I.H., Extramural
- Surgifoam and mitoxantrone in the glioblastoma multiforme postresection cavity: the first step of locoregional chemotherapy through an ad hoc-placed catheter: technical note.
Ferroli P, Broggi M, Franzini A, et al. · Neurosurgery · 2006Clinical Trial
- Fatal intraoperative cardiac arrest after application of surgifoam into a bleeding iliac screw defect.
Skovrlj B, Motivala S, Panov F, et al. · Spine (Phila Pa 1976) · 2014Case Reports
- Chondrogenic differentiation of adipose-derived adult stem cells in agarose, alginate, and gelatin scaffolds.
Awad HA, Wickham MQ, Leddy HA, et al. · Biomaterials · 2004Comparative Study, Evaluation Study
Other devices of this type
Also filed under product code LMF.
- Floseal Hemostatic MatrixBaxter Healthcare Corp · PMA 2015
- Vitagel Surgical HemostatStryker Corp. · PMA 2013
- SURGIFLO Hemostatic Matrix Kit with ThrombinFerrosan Meidcal Devices A/S · PMA 2025
- Helistat Absorbable Collagen Hemostatic Sponge/OraFOAM Absorbable Collagen Hemostatic SpongeIntegra LifeSciences Corporation · PMA 2019
- Instat Collagen Absorbable HemostatETHICON, Inc. · PMA 2007
- Avitene Flowable Collagen HemostatDavol Inc., Sub. C. R. Bard, Inc. · PMA 2025
- Collastat Absorbable Collagen Hemostatic AgentsIntegra LifeSciences Corporation · PMA 2009
- Floseal (R) Matrix Hemostatic Sealant and Proceed (Tm) Hemostatic SealantBaxter Healthcare Corp · PMA 2001
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.